Advertisement

Current Psychiatry Reports

, Volume 14, Issue 6, pp 696–704 | Cite as

An Update on Antidepressant Use in Bipolar Depression

  • Michelle M. Sidor
  • Glenda M. MacQueen
Bipolar Disorders (MA Frye, Section Editor)

Abstract

The effective treatment of depression in people with bipolar disorder remains a clinical challenge. The role of antidepressant medication in treating bipolar depression has been controversial. While early studies and meta-analyses supported a role for antidepressant medication, more recent, high quality randomized controlled trials in bipolar depression have generally not demonstrated efficacy for antidepressant medications. Although the risk of affective switch and long-term de-stabilization remains a concern when using antidepressant medications in bipolar disorder, the magnitude of this risk has been difficult to ascertain with confidence. Maintenance use of antidepressant medication has generally not demonstrated a favorable risk-benefit ratio. Future studies should explore the patient characteristics and response patterns that predict a more favorable response profile to antidepressants amongst patients with bipolar disorder so that the medications can be rationally used in those who are most likely to benefit.

Keywords

Bipolar disorder Major depression Bipolar depression Antidepressant Response Remission Switch Treatment outcome Prescribing guidelines Pharmacotherapy Psychiatry 

Notes

Acknowledgments

The authors would like to thank Dr. David Kupfer and Dr. Holly Swartz for their thoughtful insight and discussion regarding topics of this review.

Disclosure

M. M. Sidor: none; G. M. MacQueen: research funding from AstraZeneca; payment for lectures including service on speakers bureaus from AstraZeneca, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, and Janssen; and payment for the development of educational presentations from the Canadian Psychiatric Association.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Frye MA, Ha K, Kanba S, et al. International consensus group on depression prevention in bipolar disorder. J Clin Psychiatry. 2011;72(10):1295–310.PubMedCrossRefGoogle Scholar
  2. 2.
    Judd LL, Akiskal HS. Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder. Curr Psychiatry Rep. 2003;5(6):417–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Altshuler LL, Post RM, Black DO, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry. 2006;67(10):1551–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Ghaemi SN. Antidepressants in bipolar depression: the clinical debate. Aust N Z J Psychiatry. 2012;46(4):298–301.PubMedCrossRefGoogle Scholar
  5. 5.
    Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry. 1979;36(5):555–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Licht RW, Gijsman H, Nolen WA, Angst J. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand. 2008;118(5):337–46.PubMedCrossRefGoogle Scholar
  7. 7.
    Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161(9):1537–47.PubMedCrossRefGoogle Scholar
  8. 8.
    Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711–22.PubMedCrossRefGoogle Scholar
  9. 9.
    •• McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163–74. A large, well designed study that examines the efficacy of an antidepressant in treating bipolar disorder compared to both placebo and another active agent. PubMedCrossRefGoogle Scholar
  10. 10.
    •• Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011;72(2):156–67. This update on an earlier meta-analyses restricted studies to good quality primary studies. PubMedCrossRefGoogle Scholar
  11. 11.
    Guyatt GH, Oxman AD, Kunz R, et al. What is “quality of evidence” and why is it important to clinicians? BMJ. 2008;336(7651):995–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Greil W, Haberle A, Haueis P, Grohmann R, Russmann S. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord. 2012;136(3):534–42.PubMedCrossRefGoogle Scholar
  13. 13.
    Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007;58(1):85–91.PubMedCrossRefGoogle Scholar
  14. 14.
    Pacchiarotti I, Valenti M, Colom F, et al. Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. J Affect Disord. 2010.Google Scholar
  15. 15.
    Chiesa A, Chierzi F, De Ronchi D, Serretti A. Quetiapine for bipolar depression: a systematic review and meta-analysis. Int Clin Psychopharmacol. 2012;27(2):76–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194(1):4–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008;10(2):323–33.PubMedCrossRefGoogle Scholar
  18. 18.
    Sidor MM, MacQueen GM. Reply to: Antidepressants in acute bipolar-depression: an inconclusive meta-analysis. J Clin Psychiatry. 2011;72(3):415.CrossRefGoogle Scholar
  19. 19.
    van der Loos ML, Mulder P, Hartong EG, et al. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand. 2010;122(3):246–54.PubMedCrossRefGoogle Scholar
  20. 20.
    van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(2):223–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Pilhatsch M, Wolf R, Winter C, Lewitzka U, Bauer M. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study. J Affect Disord. 2010;126(3):453–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Bauer M, Zaninelli R, Muller-Oerlinghausen B, Meister W. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J Clin Psychopharmacol. 1999;19(2):164–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Li CT, Bai YM, Huang YL, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry. 2012;200(1):45–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Goodwin GM. Bipolar depression and treatment with antidepressants. Br J Psychiatry. 2012;200(1):5–6.PubMedCrossRefGoogle Scholar
  25. 25.
    • Tondo L, Vazquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121(6):404–14. This paper synthesizes information on switch associated with antidepressant treatment. PubMedCrossRefGoogle Scholar
  26. 26.
    Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158(6):906–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Keck Jr PE, Corya SA, Altshuler LL, et al. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry. 2005;66(5):611–6.PubMedCrossRefGoogle Scholar
  28. 28.
    • Perlis RH, Ostacher MJ, Goldberg JF, et al. Transition to mania during treatment of bipolar depression. Neuropsychopharmacology. 2010;35(13):2545–52. This study examined clinical features associated with greatest transition hazard for patients transitioning from depression to mania or a mixed state in 2166 people with bipolar I or II in a major depressive episode. PubMedCrossRefGoogle Scholar
  29. 29.
    Undurraga J, Baldessarini RJ, Valenti M, et al. Bipolar depression: clinical correlates of receiving antidepressants. J Affect Disord. 2012;139(1):89–93.PubMedCrossRefGoogle Scholar
  30. 30.
    Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand. 2008;118(5):347–56.PubMedCrossRefGoogle Scholar
  31. 31.
    •• Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry. 2010;71(4):372–80. This is one of the few studies examining the utility of long term treatment with antidepressants in bipolar disorder. PubMedCrossRefGoogle Scholar
  32. 32.
    Strejilevich SA, Martino DJ, Marengo E, et al. Long-term worsening of bipolar disorder related with frequency of antidepressant exposure. Ann Clin Psychiatry. 2011;23(3):186–92.PubMedGoogle Scholar
  33. 33.
    • Post RM, Leverich GS, Altshuler LL, et al. Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients. J Clin Psychiatry. 2012. The authors found that it is the repeated use of antidepressants to treat episodes of depression that is related to poor prospective response to naturalistic treatment. Google Scholar
  34. 34.
    Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189:124–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006;163(2):232–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Bond DJ, Noronha MM, Kauer-Sant’Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2008;69(10):1589–601.PubMedCrossRefGoogle Scholar
  37. 37.
    Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry. 2011;72(3):356–66.PubMedCrossRefGoogle Scholar
  38. 38.
    Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression–lack of manic induction. J Affect Disord. 2005;87(1):121–30.PubMedCrossRefGoogle Scholar
  39. 39.
    Amsterdam JD, Shults J, Brunswick DJ, Hundert M. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate. Bipolar Disord. 2004;6(1):75–81.PubMedCrossRefGoogle Scholar
  40. 40.
    Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol. 2008;28(2):171–81.PubMedCrossRefGoogle Scholar
  41. 41.
    Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. J Affect Disord. 2006;92(2–3):205–14.PubMedCrossRefGoogle Scholar
  42. 42.
    Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol. 2010;30(3):306–11.PubMedCrossRefGoogle Scholar
  43. 43.
    Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry. 2010;167(7):792–800.PubMedCrossRefGoogle Scholar
  44. 44.
    Gao K, Kemp DE, Ganocy SJ, et al. Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar Disord. 2008;10(8):907–15.PubMedCrossRefGoogle Scholar
  45. 45.
    Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry. 1988;145(2):179–84.PubMedGoogle Scholar
  46. 46.
    Mendlewicz J, Massat I, Linotte S, et al. Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. Int Clin Psychopharmacol. 2010;25(5):297–301.PubMedCrossRefGoogle Scholar
  47. 47.
    Valenti M, Pacchiarotti I, Bonnin CM, et al. Risk factors for antidepressant-related switch to mania. J Clin Psychiatry. 2012;73(2):e271–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Pacchiarotti I, Valenti M, Bonnin CM, et al. Factors associated with initial treatment response with antidepressants in bipolar disorder. Eur Neuropsychopharmacol. 2011;21(5):362–9.PubMedCrossRefGoogle Scholar
  49. 49.
    •• Kemp DE, Ganocy SJ, Brecher M, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord. 2011;130(1–2):171–9. The importance of early response and nonresponse in predicting eventual outcome has been examined in major depression but not bipolar disorder. This paper examines the predictive value of early (non) response in patients with bipolar depression. PubMedCrossRefGoogle Scholar
  50. 50.
    Li J, Kuk AY, Rush AJ. A practical approach to the early identification of antidepressant medication non-responders. Psychol Med. 2011;1-8.Google Scholar
  51. 51.
    Nakajima S, Uchida H, Suzuki T, et al. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(8):1983–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Lin CH, Lane HY, Chen CC, Juo SH, Yen CF. Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. Psychiatry Clin Neurosci. 2011;65(5):510–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000;157(9):1423–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Tohen M, Case M, Trivedi MH, et al. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry. 2010;71(4):451–62.PubMedCrossRefGoogle Scholar
  55. 55.
    Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344–53.PubMedCrossRefGoogle Scholar
  56. 56.
    Connolly KR, Thase ME. The clinical management of bipolar disorder: a review of evidence-based guidelines. Prim Care Companion CNS Disord. 2011;13(4).Google Scholar
  57. 57.
    • NICE. NICE clinical guidelines. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Clinical Excellence, update 2009. 2009. This is a high quality approach to guideline development for patients with bipolar disorder. Google Scholar
  58. 58.
    Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346–88.PubMedCrossRefGoogle Scholar
  59. 59.
    Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225–55.PubMedCrossRefGoogle Scholar
  60. 60.
    American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 Suppl):1–50.Google Scholar
  61. 61.
    Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81–109.PubMedCrossRefGoogle Scholar
  62. 62.
    Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 1989;4(4):313–22.PubMedCrossRefGoogle Scholar
  63. 63.
    Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004;65(12):1715–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079–88.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of PsychiatryUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Department of Psychiatry, Hotchkiss Brain Institute, Faculty of MedicineUniversity of CalgaryCalgaryCanada

Personalised recommendations